Can I Take Folate with Spironolactone?

What Is Spironolactone and Why Do People Take It?

Spironolactone is a synthetic aldosterone antagonist originally approved by the FDA for hypertension, edema, and heart failure [1]. Clinicians prescribe it off-label at doses of 50 to 200 mg/day for hormonal acne and hirsutism in women because it blocks androgen receptors in the skin and reduces sebaceous gland activity [2].

Mechanism of Action

At low doses (50 to 100 mg/day), spironolactone binds androgen receptors competitively, reducing dihydrotestosterone (DHT)-driven sebum production. At higher doses, it also inhibits aldosterone, causing mild natriuresis and potassium retention. A 2012 retrospective study published in the Journal of the American Academy of Dermatology (N=110) found that 66% of women with hormonal acne achieved clear or almost-clear skin after six months of spironolactone therapy [2].

What Spironolactone Does NOT Affect

Spironolactone does not interfere with folate absorption, folate metabolism, or the enzymes responsible for converting dietary folate to its active form, 5-methyltetrahydrofolate (5-MTHF). Its metabolism occurs primarily via hepatic CYP3A4 pathways, producing active metabolites including canrenone and 7-alpha-thiomethylspironolactone [3]. None of these metabolites inhibit dihydrofolate reductase (DHFR) or methylenetetrahydrofolate reductase (MTHFR).

What Is Folate and Why Might You Take It?

Folate is the generic term for a family of water-soluble B-vitamins (B9) essential for one-carbon metabolism, DNA synthesis, and methylation reactions [4]. Folic acid is the synthetic, fully oxidized form used in most supplements and fortified foods. 5-MTHF (methylfolate) is the biologically active form that crosses the blood-brain barrier and enters the methylation cycle directly.

Common Reasons to Supplement

People supplement folate for pregnancy planning (the U.S. Preventive Services Task Force recommends 400 to 800 mcg/day starting at least one month before conception) [5], for MTHFR polymorphism management, for depression adjunct therapy, or simply to maintain adequate B9 status while on dietary restrictions.

Folic Acid vs. Methylfolate

Folic acid requires a four-step enzymatic conversion to become 5-MTHF. The MTHFR C677T polymorphism, carried by roughly 10 to 15% of people of European ancestry [6], reduces this conversion efficiency by up to 70% in homozygous carriers. For those individuals, supplementing directly with 5-MTHF (methylfolate) bypasses the bottleneck entirely. Spironolactone does not worsen MTHFR conversion; the choice between folic acid and methylfolate is independent of spironolactone use.

Is There a Pharmacokinetic Interaction Between Folate and Spironolactone?

No pharmacokinetic interaction exists. A pharmacokinetic interaction would require one substance to alter the absorption, distribution, metabolism, or excretion of the other.

Absorption

Folate is absorbed in the proximal jejunum via the proton-coupled folate transporter (PCFT, encoded by SLC46A1) [7]. Spironolactone is absorbed in the small intestine via passive diffusion and is highly lipophilic. The two compounds use entirely separate transport mechanisms, so co-ingestion does not affect absorption of either.

Metabolism

Spironolactone is metabolized by CYP3A4 [3]. Folate metabolism depends on DHFR, MTHFR, and methionine synthase, none of which are CYP enzymes [4]. There is no enzyme competition between these pathways.

Excretion

Spironolactone metabolites are excreted renally and via bile. Excess folate is excreted renally as well, but through different tubular transport proteins. No competitive inhibition of renal excretion has been reported in the published literature.

Is There a Pharmacodynamic Interaction?

No pharmacodynamic interaction has been identified. A pharmacodynamic interaction would require the two substances to produce additive, synergistic, or antagonistic effects on the same physiological target.

Spironolactone's primary pharmacodynamic effects are aldosterone blockade (raising potassium, reducing sodium reabsorption) and androgen receptor antagonism [1]. Folate's pharmacodynamic role is as a cofactor in one-carbon transfer reactions supporting nucleotide synthesis, amino acid metabolism, and methylation [4]. These are unrelated biological systems. No trial, case report, or drug database entry on the FDA Adverse Event Reporting System has flagged a clinically meaningful pharmacodynamic signal between the two.

The table below summarizes the interaction assessment using the standard pharmacological framework applied by the HealthRX clinical team:

| Domain | Spironolactone | Folate | Interaction? | |---|---|---|---| | Absorption transporter | Passive diffusion (lipophilic) | PCFT (SLC46A1) | None | | Metabolizing enzyme | CYP3A4 | DHFR / MTHFR | None | | Renal excretion | Canrenone (active metabolite) | Excess 5-MTHF | None | | Pharmacodynamic target | Aldosterone receptor / androgen receptor | One-carbon methylation enzymes | None | | Effect on potassium | Raises serum K+ | No effect on K+ | None | | Effect on folate cycle | None | Supports methylation | None |

When Could Folate Supplementation Become Relevant on Spironolactone?

The answer is: rarely, and only because of other drugs in the regimen, not because of spironolactone itself.

Trimethoprim Co-Prescription

Trimethoprim (used in combination antibiotics like trimethoprim-sulfamethoxazole for acne or UTIs) inhibits DHFR, reducing conversion of folic acid [8]. If a clinician prescribes both spironolactone and trimethoprim, the folate-relevant interaction is between trimethoprim and folate, not spironolactone and folate. Supplementing 400 to 800 mcg of methylfolate daily is reasonable in this scenario to partially offset DHFR inhibition, though trimethoprim's DHFR inhibition in humans is far weaker than in bacteria.

Anticonvulsants

Phenytoin, valproate, and carbamazepine deplete folate by multiple mechanisms including reduced intestinal absorption and increased hepatic catabolism [9]. Some women with hormonal conditions take both spironolactone and an anticonvulsant. In that case, supplemental folate at 1 to 5 mg/day is commonly recommended by neurologists, and the anticonvulsant is the driver of that recommendation, not spironolactone [9].

Methotrexate

Low-dose methotrexate for psoriasis or rheumatoid arthritis is sometimes used alongside spironolactone. Methotrexate inhibits DHFR directly [10]. The American College of Rheumatology guidelines recommend routine folic acid (1 mg/day) or folinic acid supplementation with methotrexate to reduce toxicity [10]. Again, the interaction is methotrexate-folate, with spironolactone a bystander.

Potassium: The Interaction That Actually Matters with Spironolactone

While folate poses no concern, the clinically significant interactions with spironolactone involve potassium. Spironolactone blocks aldosterone-mediated potassium excretion, raising serum potassium by an average of 0.3 to 0.4 mEq/L at doses used for acne (50 to 100 mg/day) [11].

Drugs That Raise Potassium Further

ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs (which reduce renal prostaglandins), and high-dose potassium supplements can combine with spironolactone to produce hyperkalemia [1]. The FDA label for spironolactone carries a warning specifically about concurrent use with other agents that raise potassium [1].

Monitoring Schedule

Baseline serum potassium and creatinine should be obtained before starting spironolactone. The 2023 ACC/AHA Heart Failure guideline recommends rechecking within one to two weeks of initiation or dose increase, then every three to six months once stable [12]. For acne patients who are young and healthy, many dermatologists check only at baseline in low-risk individuals, but the frequency should be guided by your prescriber.

Dosing Folate Alongside Spironolactone

Because no interaction exists, no special timing or dose adjustment is needed for folate when taking spironolactone.

Standard Dosing

The standard dietary reference intake for folate in adults is 400 mcg/day as dietary folate equivalents [4]. Supplemental doses commonly range from 400 mcg to 1 mg/day for general health. Women planning pregnancy should take 400 to 800 mcg/day starting at least one month before conception, per the USPSTF recommendation published in 2023 [5].

MTHFR Carriers

Homozygous MTHFR C677T carriers may benefit from 400 to 800 mcg/day of 5-MTHF (methylfolate) rather than folic acid, since enzymatic conversion is impaired [6]. The dose remains the same; only the form changes. Neither the MTHFR status nor the choice of folate form requires any adjustment to the spironolactone regimen.

Upper Tolerable Intake

The tolerable upper intake level (UL) for folic acid in adults is 1,000 mcg (1 mg)/day from supplements and fortified foods, set by the Institute of Medicine to prevent masking of vitamin B12 deficiency [4]. Methylfolate does not carry the same B12-masking concern because it is not taken up by hematopoietic precursors the same way folic acid is, though high-dose supplementation with any B9 form should be discussed with a clinician.

What the Literature Shows on Spironolactone Safety with Common Supplements

A 2020 systematic review in the British Journal of Dermatology assessed spironolactone tolerability across 24 studies (N=3,128 women) and found that the most frequently reported adverse events were menstrual irregularities (22%), breast tenderness (8%), and hyperkalemia (2%) [13]. No folate-related adverse events appeared in any of the included studies.

The absence of a signal in this dataset, combined with the mechanistic analysis above, supports the conclusion that folate does not alter spironolactone's safety profile. The 2% hyperkalemia rate in that review occurred predominantly in women with renal impairment or concurrent potassium-raising medications, not in those taking vitamins or B-complex supplements.

Practical Guidance: What to Tell Your Prescriber

Before starting any supplement alongside a prescription medication, share your full supplement list with your prescribing clinician. For folate and spironolactone specifically, the conversation is low-complexity.

Bring these data points to your appointment:

• The form of folate you are using (folic acid vs. 5-MTHF).
• The daily dose in micrograms.
• Any other medications that affect folate metabolism (trimethoprim, anticonvulsants, methotrexate).
• Your most recent serum potassium result if available.

The American Academy of Dermatology's 2016 guidelines on acne management note that spironolactone is "a safe and effective option for women with hormonal acne" when appropriate monitoring is in place [14]. Folate supplementation does not change that monitoring protocol.

The Endocrine Society's 2018 clinical practice guideline on polycystic ovary syndrome, a condition frequently treated with spironolactone, does not list folate as a supplement requiring caution with spironolactone use, though it does recommend folic acid supplementation for women of reproductive age because of ovulatory disruption [15].

Special Populations

Pregnancy and Spironolactone

Spironolactone is category D for pregnancy (FDA labeling) due to anti-androgenic effects on male fetal genitalia in animal studies [1]. It should be discontinued before conception. Because folate is actively recommended before and during pregnancy [5], this creates no conflict: women stop spironolactone when trying to conceive and continue or start folate at that same time.

Renal Impairment

Patients with chronic kidney disease (CKD) stages 3b-5 face elevated hyperkalemia risk on spironolactone and may also have impaired renal folate handling. The 2012 KDIGO CKD guideline does not contraindicate folate supplementation in CKD, but recommends monitoring B-vitamin status given altered clearance [16]. In advanced CKD, the priority is potassium management, not folate dosing.

Older Adults

Older adults may have lower dietary folate intake and are more likely to have renal impairment affecting spironolactone metabolism. Folate supplementation at 400 mcg/day remains safe. Serum creatinine and eGFR should be used to assess spironolactone suitability rather than folate status [12].